A novel insertion mutation on exon 20 of epidermal growth factor receptor, conferring resistance to erlotinib

Case Reports in Oncology

Volumn 7, Issue 2, 2014, Pages 491-496

  Khan, Nawazish A ^a   Mirshahidi, Saied ^a   Mirshahidi, Hamid R ^a  

^a LOMA LINDA UNIVERSITY HEALTH   (United States)

Author keywords

Epidermal growth factor receptor; Erlotinib; Exon 20; Mutations; Non small cell lung cancer; Tyrosine kinase receptor inhibitors

Indexed keywords

EID: 84924070298     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000365325     Document Type: Article

References (13)

1. Herbst S: Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59(suppl 2):21-26
2. Jänne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarin AT, Fidias P, Lynch TJ, Johnson BE: Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study. Lung Cancer 2004;44:221-230
3. Yuan S, Yu SL, Chen HY, Hsu YC, Su KY, Chen HW, Chen CY, Yu CJ, Shih JY, Chang YL, Cheng CL, Hsu CP, Hsia JY, Lin CY, Wu G, Liu CH, Wang CD, Yang KC, Chen YW, Lai YL, Hsu CC, Lin TC, Yang TY, Chen KC, Hsu KH, Chen JJ, Chang GC, Li KC, Yang PC: Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations. J Clin Oncol 2011;29:3435-3442
4. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC: Effectiveness of tyrosine kinase inhibitors on 'uncommon' epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011;17:3812-3821
5. Yasuda H, Kobayash Si, Costa DB: EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2012;13:e23-e31
6. Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, Zakowski MF, Kris MG, Ladanyi M: EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 2013;12:220-229
7. Wu JY, Wu SG, Yang CH, Gow CH, Chang YL, Yu CJ, Shih JY, Yang PC: Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res 2008;14:4877-4882
8. Lund-Iversen M, Kleinberg L, Fjellbirkeland L, Helland Å, Brustugun OT: Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. J Thorac Oncol 2012;7:1471-1473
9. Chen CH, Gow CH, Yu CJ, Shih JY, Hsu YC, Lee WY, Yang PC, Kuo SH: Clinical response of gefitinib on malignant pleural effusions in patients with non-small cell lung cancer. J Cancer Mol 2008;4:23-28
10. Masago K, Fujita S, Irisa K, Kim YH, Ichikawa M, Mio T, Mishima M: Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I). Jpn J Clin Oncol 2010;40:1105-1109
11. Sasaki H, Endo K, Takada M, Kawahara M, Kitahara N, Tanaka H, Okumura M, Matsumura A, Iuchi K, Kawaguchi T, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y: EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer 2007;58:324-328
12. Zupa A, Vita G, Landriscina M, Possidente L, Aieta M, Tartarone A, Improta G: Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC. Med Oncol 2012;29:3198-201
13. Yasuda H, Sng NJ, Yeo WL, Figueiredo-Pontes LL, Kobayashi S, Costa DB: Sensitivity of EGFR exon 20 insertion mutations to EGFR inhibitors is determined by their location within the tyrosine kinase domain of EGFR (abstract 23). Cancer Res 2012;72:23.